NCT00628745

Transthyretin Amyloidosis Outcome Survey (THAOS)

Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 6,718 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate. The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.

Detailed description

n/a NA

Conditions

• Transthyretin Gene Mutations
• Transthyretin Amyloidosis

Interventions

Type	Name	Description
OTHER	None. Observational Study.

Timeline

• Start date: 2008-01-04
• Primary completion: 2023-06-16
• Completion: 2023-06-19
• First posted: 2008-03-05
• Last updated: 2024-11-22
• Results posted: 2024-11-22

Locations

113 sites across 25 countries: United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Cyprus, Denmark, France, Germany, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Portugal, Romania, Saudi Arabia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Arab Emirates

Regulatory

• FDA-regulated drug study